Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5358108 | 0.95 | HSD17B10 (0.33) | HSD17B10 | |
| SCHEMBL7784272 | 0.85 | HSD17B10 (0.32) | HSD17B10 | |
| SCHEMBL3763099 | 0.84 | HSD17B10 (0.41) | HSD17B10MEN1KMT2A | |
| SCHEMBL182607 | 0.81 | HSD17B10 (0.40) | HSD17B10MEN1KMT2A | |
| Tromethamine SCHEMBL7028618 | 0.77 | MEN1 (0.34) | HSD17B10MEN1KMT2A | |
| SCHEMBL1711725 | 0.75 | HSD17B10 (0.47) | HSD17B10MEN1KMT2A | |
| SCHEMBL4951694 | 0.74 | HSD17B10 (0.35) | HSD17B10 | |
| SCHEMBL15299589 | 0.73 | — | — | |
| SCHEMBL5351309 | 0.73 | — | — | |
| SCHEMBL10019857 | 0.73 | HSD17B10 (0.36) | HSD17B10MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383862-B2 | Salt compound, cationic polymerization initiator and cationically polymerizable composition | ADEKA CORPORATION (JP) | 2013-02-26 | — | — | US | disclosed |
| US-20100267857-A1 | SALT COMPOUND, CATIONIC POLYMERIZATION INITIATOR AND CATIONICALLY POLYMERIZABLE COMPOSITION | ADEKA CORPORATION (JP) | 2010-10-21 | — | — | US | disclosed |
| US-7217676-B2 | Hydrophobization and silica for supported catalyst | EXXON MOBIL CHEMICAL PATENTS INC. (US) | 2007-05-15 | — | — | US | disclosed |
| EP-1704171-A2 | HYDROPHOBIZATION AND SILICA FOR SUPPORTED CATALYST | ExxonMobil Chemical Patents Inc. (US) | 2006-09-27 | — | — | EP | disclosed |
| WO-2005075526-A2 | HYDROPHOBIZATION AND SILICA FOR SUPPORTED CATALYST | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2005-08-18 | — | — | WO | disclosed |
| US-20050159299-A1 | Hydrophobization and silica for supported catalyst | EXXONMOBIL CHEMICAL PATENTS INC. | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267857-A1 | SALT COMPOUND, CATIONIC POLYMERIZATION INITIATOR AND CATIONICALLY POLYMERIZABLE COMPOSITION | RFC5, RER1, ARF5 | HSD17B10 3559/4885MEN1 2796/4885KMT2A 3677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.